Applied Molecular Transport 過去の業績

過去基準チェック /06

Applied Molecular Transportの収益は年平均-25.6%で減少しているが、Biotechs業界はgrowingで19.3%年平均の収益となった。

主要情報

-25.6%

収益成長率

13.3%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	n/a
株主資本利益率	-460.5%
ネット・マージン	n/a
前回の決算情報	30 Sep 2023

Recent updates

Here's Why We're A Bit Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Mar 07

We're A Little Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Nov 13

Applied Molecular Transport GAAP EPS of -$0.93

Aug 04

Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky

Jul 27

Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data

Jul 05

Applied Molecular: Interesting Drug Delivery Approach For The GI Tract

May 03

We're Keeping An Eye On Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Apr 28

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Jan 08

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Aug 29

Applied Molecular Transport (NASDAQ:AMTI) Is In A Good Position To Deliver On Growth Plans

Apr 05

Have Insiders Been Buying Applied Molecular Transport Inc. (NASDAQ:AMTI) Shares This Year?

Feb 11

Here's Why We're Not Too Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Dec 21

Applied Molecular Transport reports Q3 results

Nov 12

収支内訳

Applied Molecular Transport の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:AMTI 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
30 Sep 23	-75	29	-11
30 Jun 23	-93	30	7
31 Mar 23	-112	32	27
31 Dec 22	-126	37	45
30 Sep 22	-134	37	64
30 Jun 22	-135	37	64
31 Mar 22	-122	35	58
31 Dec 21	-100	29	41
30 Sep 21	-89	25	58
30 Jun 21	-80	20	27
31 Mar 21	-72	16	23
31 Dec 20	-67	13	54
30 Sep 20	-55	10	30
30 Jun 20	-46	7	46
31 Mar 20	-38	6	33
31 Dec 19	-28	4	24

質の高い収益: AMTIは現在利益が出ていません。

利益率の向上: AMTIは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: AMTIは利益が出ておらず、過去 5 年間で損失は年間25.6%の割合で増加しています。

成長の加速: AMTIの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: AMTIは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: AMTIは現在利益が出ていないため、自己資本利益率 ( -460.5% ) はマイナスです。

Applied Molecular Transport 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

Applied Molecular Transport Files Form 15

Applied Molecular Transport Inc.(NasdaqCM:AMTI) dropped from NASDAQ Composite Index

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

New minor risk - Shareholder dilution

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

New major risk - Market cap size

Applied Molecular Receives Letter from Nasdaq Regarding Listing Rule 5100

New major risk - Revenue and earnings growth

New major risk - Market cap size

Applied Molecular Transport Inc. Announces Executive Changes

Price target decreased by 39% to US$0.90

Here's Why We're A Bit Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Applied Molecular Transport Receives Non-Compliance Notice From Nasdaq

Applied Molecular Transport Inc. Announces Resignation of Randall Mrsny from the Board of Directors

Applied Molecular Transport Inc. Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

Independent Director recently bought US$150k worth of stock

Price target increased to US$13.67

We're A Little Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Applied Molecular Transport Completes Enrollment of Phase 2 Lombard Monotherapy Trial of Oral Amt-101 in Patients with Moderate-To-Severe Ulcerative Colitis

Forecast to breakeven in 2024

Applied Molecular Transport GAAP EPS of -$0.93

Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky

Applied Molecular Transport Announces Top-Line Phase 2 Results from Market Combination Trial of Oral AMT-101 in Patients with Moderate-To-Severe Ulcerative Colitis

Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data

Applied Molecular Transport Inc.(NasdaqGS:AMTI) dropped from Russell 2000 Growth Index

Independent Director recently bought US$211k worth of stock

Insider recently bought US$306k worth of stock

Price target decreased to US$54.08

Applied Molecular: Interesting Drug Delivery Approach For The GI Tract

We're Keeping An Eye On Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate

Applied Molecular Transport to Report Top-Line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

Price target decreased to US$58.28

Applied Molecular Transport Inc., Annual General Meeting, May 24, 2022

Applied Molecular Transport Inc. Appoints Charlene Banard to Its Board of Directors

Price target decreased to US$69.00

Independent Director recently bought US$318k worth of stock

Less than half of directors are independent

Applied Molecular Transport Inc. Announces Management Changes

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Chief Medical Officer exercised options to buy US$458k worth of stock.

Co-Founder recently bought US$52k worth of stock

Insider recently bought US$250k worth of stock

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

Chief Financial Officer exercised options and sold US$255k worth of stock

Chief Business & Strategy Officer exercised options and sold US$289k worth of stock

Independent Chairman recently sold US$8.7m worth of stock

Applied Molecular Transport Inc.(NasdaqGS:AMTI) dropped from Russell 2500 Value Index

Chief Medical Officer exercised options and sold US$393k worth of stock

Applied Molecular Transport (NASDAQ:AMTI) Is In A Good Position To Deliver On Growth Plans

Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126

New 90-day high: US$64.47

Applied Molecular Transport Inc. Enter into a Lease Agreement with Are-East Jamie Court, LLC

Have Insiders Been Buying Applied Molecular Transport Inc. (NASDAQ:AMTI) Shares This Year?

New 90-day high: US$39.85

Applied Molecular Transport Inc. Appoints Douglas Rich as Chief Technical Officer

New 90-day high: US$34.38

Here's Why We're Not Too Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation

Applied Molecular Transport reports Q3 results

Applied Molecular Transport Announces Publication of Preclinical Data Demonstrating Potential of Novel Oral Il-10 Biologic Therapeutic (Amt-101) for Inflammatory Diseases in the Journal of Immunology

New 90-day high: US$35.00

New 90-day high - US$31.11

Applied Molecular Transport Inc. announced that it has received $32.999975 million in funding

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06